Docetaxel Injection, Solution
Product Images NDC 66758-050

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 66758-050). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Docetaxel Sandoz 01

Chemical structure of docetaxel, the active ingredient in the Docetaxel 10 mg/mL intravenous injection by Sandoz Inc. The diagram shows its molecular arrangement with rings and functional groups typical of the taxane class.*

FDA Label Image

Docetaxel Sandoz 02

A line chart displaying Disease-Free Survival (DFS) Probability (%) over time in months. It compares two treatment groups labeled as TAC (solid line) and FAC (dashed line) with DFS probability percentages on the vertical axis and Disease-Free Survival Time (months) on the horizontal axis, showing trends in DFS over approximately 66 months.*

FDA Label Image

Docetaxel Sandoz 03

A Kaplan-Meier survival curve graph showing survival probability (%) on the vertical axis versus survival time (months) on the horizontal axis. Two treatment groups are compared: TAC (solid line) and FAC (dashed line), with TAC demonstrating a slightly higher survival probability over time than FAC.*

FDA Label Image

Docetaxel Sandoz 04

A Kaplan-Meier survival curve chart displaying overall survival probability over time in months. The graph compares two treatment groups labeled T75 and BSC, with cumulative probability on the vertical axis and survival time on the horizontal axis. A log-rank p-value of 0.010 is indicated, reflecting statistical analysis between the groups.*

FDA Label Image

Docetaxel Sandoz 05

A survival curve chart depicting cumulative probability of overall survival over time in months for two groups labeled T75 and VI. The graph shows a decline in survival probability from 0 to 18-21 months, with the Log-rank p-value reported as 0.13.*

FDA Label Image

Docetaxel Sandoz 06

A survival probability curve illustrating the relationship between survival probability and survival time in months. The graph features two lines labeled T75 q3w and M q3w, representing different treatment groups or regimens, with survival probability decreasing over time up to 30 months.*

FDA Label Image

Docetaxel Sandoz 07

A survival probability graph displaying two curves labeled TCF and CF over a 24-month period. The y-axis represents probability in percentage, and the x-axis represents time in months. The graph compares the survival probabilities of the two groups across time.*

FDA Label Image

Docetaxel Sandoz 08

A survival probability curve chart showing survival time in months on the horizontal axis and survival probability percentage on the vertical axis. Two curves labeled TCF and CF are plotted, indicating different survival trends over a 36-month period.*

FDA Label Image

Docetaxel Sandoz 09

A line graph depicting progression-free survival time in months on the x-axis and the percentage of patients surviving on the y-axis. Two lines are shown representing two groups labeled TNP and TTP, illustrating comparative survival rates over a period extending up to 42 months.*

FDA Label Image

Docetaxel Sandoz 10

A survival curve graph depicting survival time in months on the x-axis versus survival percentage on the y-axis. Two survival curves are shown, labeled TMF and DPBS, illustrating comparative survival over time.*

FDA Label Image

Docetaxel Sandoz 11

A survival curve graph showing percentage survival over time in months for two groups labeled TPF and PF. The x-axis represents survival time in months up to 72, and the y-axis shows survival percentage from 0 to 100%. A table below the x-axis indicates the number of patients at risk at various time points for each group.*

FDA Label Image

Docetaxel Sandoz 12

Packaging label for Docetaxel Injection 20 mg/2 mL (10 mg/mL) solution for intravenous infusion by Sandoz Inc. The label indicates a 2 mL multiple-dose vial and highlights the cytotoxic nature of the agent and storage instructions between 2° and 25°C. It includes manufacturer details and a note to refer to the package insert for administration instructions.*

FDA Label Image

Docetaxel Sandoz 13

Packaging label for Docetaxel Injection 80 mg/8 mL (10 mg/mL) solution for intravenous infusion, in an 8 mL multiple-dose vial. The label shows the product name, strength, concentration, and usage caution stating it is a cytotoxic agent for intravenous infusion only. Manufactured for Sandoz Inc., with manufacturing by FAREVA Unterach GmbH in Austria. Storage instructions and product origin (Mexico) are noted.*

FDA Label Image

Docetaxel Sandoz 14

Packaging label for Docetaxel Injection 160 mg/16 mL (10 mg/mL) solution for intravenous infusion. The label shows it is a cytotoxic agent for intravenous use only, manufactured by Sandoz Inc. and Fareva Unterach GmbH. It includes storage instructions and a note about concentration checking before preparation. The label design uses purple, red, and white colors, and features barcode and regulatory information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.